Manara - Qatar Research Repository
Browse
DOCUMENT
1-s2.0-S0969996123001614-main.pdf (11.04 MB)
DATASET
supp_1-s2.0-S0969996123001614-mmc15.xlsx (49.2 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc16.xlsx (310.63 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc17.xlsx (239.97 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc18.xlsx (291.12 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc19.xlsx (18.07 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc20.xlsx (17.4 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc21.xlsx (10.71 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc22.xlsx (32.73 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc23.xlsx (218.42 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc24.xlsx (9.53 MB)
DATASET
supp_1-s2.0-S0969996123001614-mmc25.xlsx (1.71 MB)
DATASET
supp_1-s2.0-S0969996123001614-mmc26.xlsx (36.37 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc27.xlsx (25.31 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc28.xlsx (64.97 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc29.xlsx (766.96 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc30.xlsx (206.34 kB)
DATASET
supp_1-s2.0-S0969996123001614-mmc31.xlsx (723.07 kB)
1/0
18 files

Uncovering a neurological protein signature for severe COVID-19

Version 3 2024-07-16, 10:45
Version 2 2023-10-22, 09:56
Version 1 2023-05-16, 08:56
journal contribution
revised on 2024-07-16, 10:43 and posted on 2024-07-16, 10:45 authored by Omar El-Agnaf, Ilham Bensmail, Maryam A.Y. Al-Nesf, James Flynn, Mark Taylor, Nour K. Majbour, Ilham Y. Abdi, Nishant N. Vaikath, Abdulaziz Farooq, Praveen B. Vemulapalli, Frank Schmidt, Khalid Ouararhni, Heba H Al-Siddiqi, Abdelilah Arredouani, Patrick Wijten, Mohammed Al-Maadheed, Vidya Mohamed-Ali, Julie Decock, Houari B. Abdesselem

Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has sparked a global pandemic with severe complications and high morbidity rate. Neurological symptoms in COVID-19 patients, and neurological sequelae post COVID-19 recovery have been extensively reported. Yet, neurological molecular signature and signaling pathways that are affected in the central nervous system (CNS) of COVID-19 severe patients remain still unknown and need to be identified. Plasma samples from 49 severe COVID-19 patients, 50 mild COVID-19 patients, and 40 healthy controls were subjected to Olink proteomics analysis of 184 CNS-enriched proteins. By using a multi-approach bioinformatics analysis, we identified a 34-neurological protein signature for COVID-19 severity and unveiled dysregulated neurological pathways in severe cases. Here, we identified a new neurological protein signature for severe COVID-19 that was validated in different independent cohorts using blood and postmortem brain samples and shown to correlate with neurological diseases and pharmacological drugs. This protein signature could potentially aid the development of prognostic and diagnostic tools for neurological complications in post-COVID-19 convalescent patients with long term neurological sequelae.

Other information

Published in: Neurobiology of Disease
License: https://creativecommons.org/licenses/by/4.0/
See article on publisher'swebsite: https://doi.org/10.1016/j.nbd.2023.106147

Funding

Open Access funding provided by the Qatar National Library.

Hamad Bin Khalifa University, Qatar Biomedical Research Institute (QB-10-ID-IDRP).

Hamad Medical Corporation (MRC-05-003).

History

Language

  • English

Publisher

Elsevier

Publication Year

  • 2023

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Bin Khalifa University
  • Qatar Biomedical Research Institute - HBKU
  • College of Health and Life Sciences - HBKU
  • Aspire Zone Foundation
  • Aspetar Orthopaedic and Sports Medicine Hospital - AZF
  • Hamad Medical Corporation
  • Hamad General Hospital - HMC
  • Weill Cornell Medicine - Qatar
  • Anti-Doping Laboratory Qatar